Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Regulus Therapeutics Inc. | ex-321x20210331.htm |
| EX-31.2 - EX-31.2 - Regulus Therapeutics Inc. | ex-312x20210331.htm |
| EX-31.1 - EX-31.1 - Regulus Therapeutics Inc. | ex-311x20210331.htm |
| EX-10.6 - EX-10.6 - Regulus Therapeutics Inc. | exhibit106-amendmentnumber.htm |
| EX-10.5 - EX-10.5 - Regulus Therapeutics Inc. | exhibit105-sdx753896xv4x.htm |
| EX-10.4 - EX-10.4 - Regulus Therapeutics Inc. | exhibit104-sdx754314xv2xre.htm |
| EX-10.3 - EX-10.3 - Regulus Therapeutics Inc. | exhibit103-sdx758866xv2xre.htm |
| 10-Q - 10-Q - Regulus Therapeutics Inc. | rgls-20210331.htm |
Exhibit 10.7
Joseph P. Hagan Yearly Discretionary Base Salary Increase
The Board of Directors (the “Board”) of Regulus Therapeutics Inc., upon the recommendation of the Compensation Committee of the Board, approved the increase of Mr. Hagan’s annual base salary to $567,500, effective January 1, 2021.